Cushing's Disease & Non-Functioning Hypothalamus-Pituitary Tumors (posters)

MON-100

A long-term follow-up study of eighteen patients with thyrotropin-secreting pituitary adenomas
Nadège C van Varsseveld, Peter H Bisschop, Nienke R. Biermasz, Alberto M. Pereira, Eric Fliers and Madeleine L. Drent

MON-101

Sellar and Suprasellar Meningiomas: A 12-year-Johns Hopkins Experience
Ratchaneewan Kwancharoen, Ari Blitz, Fabiana Tavares, Patrizio Caturegli and Roberto Salvatori

MON-103

MON-104

High prevalence of metabolic syndrome features in patients previously treated for non-functioning pituitary macroadenoma
Sjoerd D. Joustra, Kim M.J.A. Claessen, Natasha M Appelman-Dijkstra, Olaf M. Dekkers, Andre P. van Beek, Bruce H.R. Wolffenbuttel, Alberto M. Pereira and Nienke R. Biermasz

MON-105

Serum Prolactin Levels are Unrelated to Pituitary Tumor Volume and Degree of Invasiveness In 114 subjects with Non-Functioning Pituitary Adenomas
John D. Carmichael, Vivien Shelley Bonert, Jaswinder Jutla, Raymundo Garcia Lora and Adam N Mamelak

MON-106

BASELINE CHARACTERISTICS AND DIFFERENCES IN SHORT- AND LONG-TERM RESPONSE TO RHGH BETWEEN GHD ADULTS WITH CRANIOPHARYNGIOMA AND NON-FUNCTIONING PITUITARY ADENOMA
Claudia Giavoli, Eriselda Profka, Silvia Bergamaschi, Emanuele Ferrante, Elena Malchiodi, Elisa Sala, Elisa Verrua, Anna Spada and Paolo Beck-Peccoz

MON-107

Clinical and Biochemical Characteristics of Apoplexy in a Pituitary Mass; Pituitary Adenoma VS Rathke's Cleft Cyst (RCC)
Ribal Al Aridi, Joumana T Chaiban, Dima Abdelmannan, Warren Selman and Baha M Arafah

MON-108

Visual dysfunction and hypopituitarism at presentation in a large cohort with non-functioning pituitary adenomas
Harriet Pearce, Gabriella Bugg, Michael William O'Reilly, Rosalind Mitchell, Alan Johnson, Neil John Gittoes, Andrew Alan Toogood and John Ayuk

MON-109

PITUITARY APOPLEXY IN PATIENTS WITH CLINICALLY NONFUNCTIONING PITUITARY ADENOMAS. A CASE-CONTROL STUDY
Guadalupe Vargas, Baldomero Gonzalez, Aldo Zarate, Adolfo Rodriguez, Victoria Mendoza and Moises Mercado

MON-111

High-dose Cabergoline Treatment of Childhood- and Adolescence-onset Prolactinomas
Nobuhiro Miki, Masami Ono, Yasufumi Seki, Rena Makino and Atsuhiro Ichihara

MON-88

Endoscopic transsphenoidal pituitary surgery: a good and safe primary treatment option for Cushing's disease, even in case of macroadenomas or invasive adenomas
Margreet A.E.M. Wagenmakers, Jeroen D. Boogaarts, Sean H.P.P. Roerink, J. André Grotenhuis, Erik J. van Lindert, Johannes W.A. Smit, Romana T. Netea-Maier and Ad RMM Hermus

MON-89

Evaluation of Late-Night Salivary Cortisol during 12 Months of Pasireotide Treatment in Patients with Cushing's Disease
Beverly MK Biller, Stephan Petersenn, Rosario Pivonello, James W. Findling, Maria Fleseriu, Andrew Trovato, Gareth Hughes, Monica Ligueros-Saylan and John Newell-Price

MON-90

Improvements in the Clinical Signs and Symptoms of Cushing's Disease Following 12 Months' Treatment with Pasireotide are Not Restricted to Patients Who Achieve UFC Control
Rosario Pivonello, Stephan Petersenn, Feng Gu, Andrew Trovato, Gareth Hughes, Monica Ligueros-Saylan, Luiz R Salgado, André Lacroix, Jochen Schopohl and Beverly MK Biller

MON-91

Incidence of Cushing's Disease in the United States
Michael S. Broder, Maureen P Neary, Eunice Chang, William H Ludlam and Dasha Cherepanov

MON-92

Multi-spectral Imaging as a Measure of Facial Plethora in Cushing Disease
Maya Beth Lodish, Yasaman Ardeshirpour, Evgenia Gourgari, Margaret Farmar Keil, Ali Afshari, Elena Belyavskaya, Charalampos Lyssikatos, Victor Chernomordik, Amir Gandjbakhche and Constantine A Stratakis

MON-93

Predictors of Quality of Life in Patients with Treated Cushing's Disease
Alessia Carluccio, Nina K. Sundaram, Sumedha Chablani, Levana G. Amrock, Jessica K. Lambert, Kalmon D. Post and Eliza B. Geer

MON-94

MON-95

Annual Economic Burden Associated with Cushing's Disease in the United States
Michael S. Broder, Maureen P Neary, Eunice Chang, William H Ludlam and Dasha Cherepanov

MON-96

The FGFR4-G388R Polymorphism Signals Through Distinct STAT3 Modifications to Regulate Pituitary Corticotroph Tumors
Tae Tateno, Toru Tateno, Lei Zheng, Maw Maw Hliang, Katsuhiko Yoshimoto, Shozo Yamada, Sylvia L. Asa and Shereen Z Ezzat

MON-97

Pasireotide Monotherapy in Cushing's Disease: a single-centre experience with 5-year extension of Phase III trial
Jessica M. MacKenzie-Feder, Isabelle Bourdeau, Sophie Vallette, Hugues Beauregard, Louis-Georges Ste-Marie and André Lacroix

MON-98

BKM120, a pure PI3K inhibitor, demonstrates stronger anti tumoral effect than BEZ235, a dual PI3K-mTOR inhibitor, on rat prolactin secreting pituitary tumor SMtTW-3
Carole Auger, Pascale Chevallier, Alexa Rachwan, Veronique Raverot, Marie Chanal, Jacqueline Trouillas and Gerald Raverot

MON-99

Polycystic ovary syndrome (PCOS) and Cushing's syndrome (CS) – a clinical conundrum
Jessica Allison Brzana, Christine G Yedinak, Nadia Hameed, Adeline Plesiu, Shirley McCartney and Maria Fleseriu